The stock of Foghorn Therapeutics Inc (FHTX) has gone down by -2.54% for the week, with a 22.00% rise in the past month and a -32.83% drop in the past quarter. The volatility ratio for the week is 12.77%, and the volatility levels for the past 30 days are 11.04% for FHTX. The simple moving average for the past 20 days is 11.87% for FHTX’s stock, with a -17.73% simple moving average for the past 200 days.
Is It Worth Investing in Foghorn Therapeutics Inc (NASDAQ: FHTX) Right Now?
Company’s 36-month beta value is 3.20.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for FHTX is 27.83M, and currently, short sellers hold a 3.30% ratio of that floaft. The average trading volume of FHTX on February 21, 2025 was 161.89K shares.
FHTX) stock’s latest price update
The stock price of Foghorn Therapeutics Inc (NASDAQ: FHTX) has dropped by -8.35 compared to previous close of 5.87. Despite this, the company has seen a fall of -2.54% in its stock price over the last five trading days. zacks.com reported 2025-02-11 that Foghorn Therapeutics (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Analysts’ Opinion of FHTX
Many brokerage firms have already submitted their reports for FHTX stocks, with B. Riley Securities repeating the rating for FHTX by listing it as a “Buy.” The predicted price for FHTX in the upcoming period, according to B. Riley Securities is $10 based on the research report published on January 30, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see FHTX reach a price target of $18. The rating they have provided for FHTX stocks is “Buy” according to the report published on September 03rd, 2024.
Evercore ISI gave a rating of “Outperform” to FHTX, setting the target price at $20 in the report published on August 19th of the previous year.
FHTX Trading at 9.46% from the 50-Day Moving Average
After a stumble in the market that brought FHTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.51% of loss for the given period.
Volatility was left at 11.04%, however, over the last 30 days, the volatility rate increased by 12.77%, as shares surge +23.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.61% lower at present.
During the last 5 trading sessions, FHTX fell by -2.54%, which changed the moving average for the period of 200-days by -11.95% in comparison to the 20-day moving average, which settled at $4.81. In addition, Foghorn Therapeutics Inc saw 13.98% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FHTX starting from Costa Carlos, who sale 35,756 shares at the price of $10.04 back on Sep 20 ’24. After this action, Costa Carlos now owns 0 shares of Foghorn Therapeutics Inc, valued at $358,990 using the latest closing price.
Costa Carlos, the Chief People Officer of Foghorn Therapeutics Inc, sale 857 shares at $10.17 during a trade that took place back on Sep 23 ’24, which means that Costa Carlos is holding 0 shares at $8,716 based on the most recent closing price.
Stock Fundamentals for FHTX
Current profitability levels for the company are sitting at:
- -3.99 for the present operating margin
- 0.88 for the gross margin
The net margin for Foghorn Therapeutics Inc stands at -3.58. The total capital return value is set at -0.4.
Based on Foghorn Therapeutics Inc (FHTX), the company’s capital structure generated 3.62 points at debt to capital in total, while cash flow to debt ratio is standing at -2.65. The debt to equity ratio resting at -1.38. The interest coverage ratio of the stock is -44.84.
Currently, EBITDA for the company is -104.45 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 11.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.77.
Conclusion
In a nutshell, Foghorn Therapeutics Inc (FHTX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
